CK Life Sciences (HKG:0775) subsidiary Sealbond sold the entire stake in Canadian company Pharmagesic to Nasdaq-listed Virios Therapeutics for $100 million, according to a Monday filing with the Hong Kong Stock Exchange.
Virios will pay for the acquisition through the issuance of 211,383 shares of purchaser common stock and 2,108.3854 shares of non-voting purchaser preferred stock, the filing said.
One purchase preferred stock will be convertible into 10,000 shares of purchaser common stock, according to the filing.
Conjoint, another CK Life Sciences subsidiary, lent HK$19.5 million to Virios, the filing said.
Both transactions will result in the business combination of Wex Pharmaceuticals, a Canada-based subsidiary of Pharmagesic, the filing said.
Shares rise 8% during Tuesday's afternoon trading.
Price (HKD): $0.55, Change: $+0.030, Percent Change: +5.77%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。